Skip to main content
. 2023 Feb 2;13:1890. doi: 10.1038/s41598-023-28830-7

Figure 3.

Figure 3

Recognition of “immunogenic” AAV8-CMV-eGFP vector lots by pDCs is TLR9 dependent. Human pDCs were treated with the TLR9 antagonist H154 (50 μM) followed by stimulation with “immunogenic” AAV8 vector lots (MOI: 1:1 × 106 vg) for 18 h. (a) Representative bright field images of purified pDCs treated with “immunogenic” AAV vector lots (upper image) or “immunogenic” AAV vector lots and H154 (lower image). Scale bar is 100 μm. (b) Cytokine release of IP-10, MIP-1β, TNF-α and IFN-α2 by stimulated pDCs. Since in the IFN-α2 measurements some values fell below the assay range, the constant 1 was added to all measured IFN-α2 values for presentation in a semi-logarithmic plot. Shown are means and standard deviations. Statistical significance was determined using one-way ANOVA and Holm-Sidak’s post hoc analysis. P values: ≤ 0.05: *; ≤ 0.01: **; ≤ 0.001: ***.